<SEC-DOCUMENT>0001193125-14-234162.txt : 20140624
<SEC-HEADER>0001193125-14-234162.hdr.sgml : 20140624
<ACCEPTANCE-DATETIME>20140612080611
ACCESSION NUMBER:		0001193125-14-234162
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140610
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140612
DATE AS OF CHANGE:		20140612

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPLIGEN CORP
		CENTRAL INDEX KEY:			0000730272
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				042729386
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14656
		FILM NUMBER:		14906024

	BUSINESS ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		7814499560

	MAIL ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d743136d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of
Report (Date of earliest event reported): June&nbsp;10, 2014 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Repligen
Corporation </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-14656</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>04-2729386</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or Other Jurisdiction<BR>of Incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Commission<BR>File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer<BR>Identification No.)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(781) 250-0111 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<I>see </I>General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;10, 2014, Nicolas M. Barthelemy was elected to the Board of Directors (the &#147;Board&#148;) of Repligen Corporation (the &#147;Company&#148;).
Mr.&nbsp;Barthelemy most recently served as President, Global Commercial Operations at Life Technologies, which position he held from early 2011 until the acquisition of Life Technologies by Thermo Fisher Scientific Corporation in 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Barthelemy will receive cash and equity compensation pursuant to the Company&#146;s non-employee director compensation policy as set forth in the
Company&#146;s Amended and Restated Director Compensation Policy (the &#147;Director Compensation Policy&#148;). Pursuant to the terms of the Director Compensation Policy, Mr.&nbsp;Barthelemy received an option to purchase 24,000 shares of Common
Stock on the date he joined the Board (the &#147;Initial Board Option&#148;). The Initial Board Option vests equally over a three-year period from the date of grant. The Initial Board Option has a term of ten years, subject to early termination in
the event of death, removal or resignation from the Board. The Initial Board Option has an exercise price equal to the closing price of the stock on the date the Initial Board Option is granted. In addition, under the Director Compensation Policy,
each non-employee director receives an annual retainer for service on the Board and committees of the Board, and except in the year following a non-employee director&#146;s first election to the Board by the stockholders, each non-employee director
reelected to the Board by the stockholders is awarded annually restricted stock units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no arrangements or understandings between
Mr.&nbsp;Barthelemy and any other persons pursuant to which Mr.&nbsp;Barthelemy was selected as a director. There have been no transactions since the beginning of the Company&#146;s last fiscal year, or any currently proposed transaction, in which
the Company was or is to be a participant, in which the amount involved exceeds $120,000, and in which Mr.&nbsp;Barthelemy had, or will have, a direct or indirect material interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has issued a press release announcing Mr.&nbsp;Barthelemy&#146;s election to the Board and has attached a copy of such press release as Exhibit
99.1 hereto. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <I>Exhibits.</I> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Press Release by Repligen Corporation, dated June&nbsp;12, 2014.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3">REPLIGEN CORPORATION</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: June&nbsp;12, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Walter C. Herlihy</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Walter C. Herlihy</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit Index </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman">Exhibit</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release by Repligen Corporation, dated June 12, 2014</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d743136dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="6">


<IMG SRC="g743136logo.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Repligen Corporation</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">41 Seyon Street</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Building #1, Suite 100</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Waltham,&nbsp;Massachusetts&nbsp;02453</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Telephone: (781) 250-0111</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Telefax: (781) 250-0115</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Repligen Appoints Nicolas M. Barthelemy to Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WALTHAM, MA &#150; June&nbsp;12, 2014</B> &#150; Repligen Corporation today announced that it has elected life sciences and biopharmaceutical industry
veteran Nicolas M. Barthelemy to its Board of Directors. Mr.&nbsp;Barthelemy brings over 20 years of industry experience to the director role, most recently as President, Global Commercial Operations at Life Technologies, a multinational life
sciences company whose acquisition by Thermo Fisher Scientific was completed earlier this year. Mr.&nbsp;Barthelemy is particularly accomplished in the areas of commercial expansion and global market development, supported by his strong background
in biologic drug manufacturing and supply chain management. <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am pleased to welcome Nicolas Barthelemy as a fitting addition to the
Repligen Board,&#148; said Walter C. Herlihy, President and Chief Executive Officer of Repligen. &#147;Mr. Barthelemy&#146;s input will have immediate value as we expand our commercial organization to market our growing portfolio of proprietary
bioprocessing products that we sell to leading biopharmaceutical manufacturers worldwide.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Barthelemy&#146;s nine-year tenure with Life
Technologies includes his most recent position of President, Global Commercial Operations, which he held from early 2011 until the acquisition of the company by Thermo Fisher Scientific Corporation in 2013. In this role, Mr.&nbsp;Barthelemy managed
an organization of 3,500 employees and was responsible for delivering close to $4 billion in revenue. Notable accomplishments were market share capture in Europe and Asia, and a shift in focus and resources from traditional research markets to
effect strong growth in applied and clinical markets. Prior to this role, Mr.&nbsp;Barthelemy led the Cells Systems division for five years, guiding the unit to achieve double-digit annual growth. A key contributor to this growth was the
bioproduction business which serves biologic drug manufacturers. Prior to Life Technologies, Mr.&nbsp;Barthelemy was with Biogen Idec for eight years in roles of increasing responsibility, most recently as Vice President, Manufacturing and General
Manager for the company&#146;s manufacturing organization at Research Triangle Park. He began his career with Merck&nbsp;&amp; Co., Inc. as a Senior Project Engineer, Vaccine Technology. Mr.&nbsp;Barthelemy received a Masters of Science degree in
Chemical Engineering from the University of California, Berkeley, and an engineering degree from Ecole Sup&eacute;rieure de Physique et Chimie Industrielles, Paris. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Repligen Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen Corporation (NASDAQ:RGEN) is a life sciences company focused on the development, production and commercialization of high-value consumable products
used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of
Protein A media that is used to separate and purify monoclonal antibody therapeutics. Our line of ATF (Alternating Tangential Flow) filtration devices and our growth factor products are used to increase product yield during the fermentation stage of
biologic drug manufacturing. In addition, we developed and market an innovative line of &#147;ready-to-use&#148; chromatography columns under our OPUS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> brand (Open Platform User Specified)
that we deliver pre-packed to our biopharmaceutical customers with their choice of purification media. Repligen&#146;s corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA and Lund, Sweden. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section&nbsp;27A of the Securities Act of
1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that express or implied statements in this press release which are not strictly historical statements, including, without limitation,
statements identified by words like &#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;seek,&#148; or &#147;could&#148; and similar expressions and any other statements regarding the expansion of
our commercial organization or our product portfolio or the general future potential of our business constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual
results to differ materially from those anticipated, including risks detailed in Repligen&#146;s annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the
Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward looking statements reflect management&#146;s current views and Repligen does not undertake
to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sondra Newman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(781) 419-1881 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>snewman@repligen.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source: Repligen Corporation </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g743136logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743136logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`)`"4`P$1``(1`0,1`?_$`',```("`@,!````````
M```````*"`D&!P$$!0,!`0`````````````````````0```&`@$#`P,"!00#
M`0````(#!`4&!P$("0`1"A(3%!46%R$C,4$B)!AQ,B4946'Q)A$!````````
M`````````````/_:``P#`0`"$0,1`#\`=HW$V&:=2M4MC-FWI*C<$5$4Q8MH
MEM*]6:@2/SG#XNY/#)&S%B<A4H39DCTF3H`#+*,,P-1CT@$+MC((NPCS%.02
MS$JY=6_&5"+"1-AY25S60=7=DL2MRHXO)Q*5<H86->4D4&E8R((#,A$(/ZXQ
MG'09,A\S+:6KIU'&[:+C0;H;%'?`%"MO0RZQ*^G1C3\TI.J>8XGL2'*FQ[PC
M`$T(2!!3E''>D.5)/;.<@\UK/L166VM`U)LI33FM=JQNB$LT[AZIS19;'8MM
M=R/48VO3;DT_#>]LRT!J-:0$PT!2H@P(1C#C`LAO+H#H#H#H*O.8KD.5\7FA
M]D[:,D,8[%F$<DE=P^$P>2.C@S,LB?IO,FIG5E+G%K(4+B"VJ,"<7#&`8#[@
MD>`>K'JZ".G'_P`IE][=<1EE\D,UUZ9H].VU@V"D-/TU6@)O-AV.34K>XL\1
M;$B`E&IECH\S:R6):V`3H"1C&7[7M8R,6>@\;@[Y!.1O?Z/[#2G?749GU+;Z
MY>*]8*L:053=-7/\W6/:*5.,U<5**XI&[*G%H8B$;240:B3E@]]4:$1@\A](
M0Q'?;G7%4&QQV@_'?K-+>0S>M*7C[QAD&<@-M1TD+L/"HNUIZD+6EIWMER(D
M3@BR)O0-V#\%+G5&J#E-D(77'R!>4+JA")!L-=W&_IC:-,Q]NQ(YM`Z*F$K>
M;(KB-,[2<M?W%68UVY,5SFE("`1ZM4@;'TE$408,00D?NX"]#BYY**9Y4M4H
M]L]3S<YQ4?UMP@UEUL^K$SB^UE9C$B;'![BBUS1E)TKVWC;GI&N;G`LDC"UO
M6$F#)3G>ZG)"Q;H#H#H#H#H%J_+&OT=*\.5L19$M+1O&Q-FU/1R'L?[2HQ`H
M?S;-DH$X`#`::4IC5:*DIW;^CVE.<"[X%VR%4OC`<AG&9H?QL*(CL%N%3=57
M3:]]V5:$NA,G='LF1,;<2DC=>15,Z$$M"A(3\UF@@7`CVACP(A>#(L^K.0A"
M$7D@\AU#<SE@Z9Z9\9C)+-M+%B,RE\A5S"%5[*&XA0ZSU!'8VUP>+BEC,PO@
MV\C*+*^0N2A.D8T19*08U0\%*!)@NTVBY`8QXS/$OI7J:WL<<M_<I14P6.(P
M-0Y*\P9ME9BPV67):,P5(5)#R?7K/84O6)FI(G&G5/:@02BC$Y12H],%0]VR
MKR[V?5A[Y+)QL$16-9Q2)J;?<*3C::FV";0^JUC8E<E4H>:?_&RYE5,3%'18
M6'H'MT72%O)`::<F`<$WH&#^$3FJE.^G&E?>S.Q[*P-EN:;$SM/<SG&$V&B/
M3Q@AM:_DQHL%*T8QA%&ECXSD*TBY$08),!8WFGDA((/*3D@L9Q8<L/D@\B<W
MO.J-9K%9[:DJ^--0#;<N*(U?&ZBU59G5Z6J!20:Q@KE"6^3R081`0,J9:0_&
M?$3KS@-2K(#%",/*'R^<Z'#IR41*BN1JY%5_15Z>(,]6+7CD.%2J)S>II\^G
MMPIQ3$J:8U%W:+.J`:=P`WDX"WI@KT(DJU%DD&`A"S7S<;]`R:^:6:QHUYH5
M5BVU/+J?4)`S`ARUU3$TT-8Q+0A,P4(I8Y6NJ$2$819R-(+(<X].>X2`WMN6
MTN';QBM38G2T]<*=V&>85K%6\=E,<&A3R%@GUA9%>EQB9RU3>I)]]2B;)"E/
M-R7Z@`5"%DS)F0Y&&/TIR8[;ZI>,&_\`(!L'<<QM7:N\G>=-=%2JQC&]>[LC
MK8=@*ZCK54WDEI2$9S;$(W%5\R2ISR<@4B+$$>!%F_J%G7CD<?D;TJXZJNL-
M\;5"[8_<*/L&Q]^3E],RNE;HIG[?F20.(+7)2(YP"AB,2>R<G$&FF9$]K'%2
M+/K49"$)QR?ESXM(E()%#9=R"Z>L4DC#R[1B3QUYORMDCDS/C*M4-3TRNJ%0
M_A-3+F]>F-(/*'C`@&`$'..^,]!'KA]UFXT]5ZHV,E7'+L(CN:E+*N!RG%ER
M!-;T'LJO*_FK3'DRUQCL?=H>RL3+%VUFB[JD,.3J3%*@I'A.(T[T!#GH*RP[
M[\L7,U9EJM7#U)JKU#T4J"7NU:J-XKEBJ:736\IPS@;CG<-2PQV8I:B21U,4
MJ+-3Y&VEF91J"S52],I-PVD!YFH.\?*SHCRMT[QA\J]OUCM+`=MH3(W_`%UV
M-AT58H8ZH9(SE29Q;VMT"PQ:$$&A<UD;4LZUJ6H%2I,L6MAR5<).(PL\,FY5
M^6K>JA.8_4#071F-(;=43>EETPF]&Y:(8478=BS/-EIH,1,+%?F5S?*XKJOD
M$/22.1*FU0A/RPA5?N%Y$4>6$3>1^R_)6XQZC(Y#[/WCU7M^LXC,80V6UK-7
M]-LK97D:;9F^H(^U(VIPD4#9Y[)XZ=(7!.VJ593VB>R/EEGEY,`$TPH&J/\`
M+`O_`*_/\YOLM7[7^''^6'X[^9CYWM_A3\O_`&7\_P!KM\OT_P!C[WH_W_U>
MG^70)?>;W?`#G+1#5]N5^H].CMB]Y2V@,[C]#@>P5Y7RL1'MY%GUC;I,6`6!
M8_@+';/\<!;1K%XJ?$DJUNH!9>&N<RD-T+:7K!=;;V.^+P8_J=EKH6RJYTK`
MRL4X96=I)-DYRKVTR=*0427V!@&.W0*<ZCTLFU/\IF&:R:-S*>1>N*]W0.JX
MXLZ4K5+P[5%#T09#>M=2IR2!*S)X[],C3RB&4L`9@T*0DPW]\O!H0W)Y&C*;
MM)Y&<!UNMFSQTK69R74:BF*UG<G"EHKF$6*F:90]SLA*Y.,?;#$C+,;&=#3A
MY7)R,F)A8,4%^@7MA9#O'PS1W4>IDZ[>KR;MJH74]M8/@Z>-V`TV]/T%D-[R
MV*QN+1BNF39&7NLLC"AJ+&%<9EM/;0%&!`H&'!I>!A]Y1KUKIQ0>-'O?.=7]
MHY#M-#]\WZ,QBO;<<Z?E='9>F><NT?IYW9&N&RIX4NYK.3%&N4+2W08$X%Y)
MV/;`<0$D9@2\\-!VH6.<;-Y+6V715';!NRTQ?KG1N;LTMCZPQ=H@D`1P1<X$
M*702L$(+;AJS4R\XI,F^<>N*#W$2,8@HRY%Y8S<Z_D@TO3&MJPZPZ6K=UJRD
MG&P8RI.<HVLK&HY0\6/?]GM3DD-RB)CB!3(GA"W+BC@)W0Q(D&0,0EA/K#9_
MD8JS]ZO(CU'TB1X"XL,1QJW0;PW$&&&EE+;EGQ=B3MR4`,-)3%C)@\Z08/\`
M0(/8I%CUC[X[`"4?FVW626FT$U-CHL>O`[0NI[CR'(\C+**+CM:5F,IM)+[9
MP8(<D(3Y#ZA?T""'&/U]0;1\E+5N8:_>/?QWTU'6U9]`UEGFM<9M;#;\DM$D
M<$VOM@0U6_NZ4D'M?&7V0[^CWE'^U8X%AR+)IN/4#D^J-BUY;NL6OEF5*N;'
M"M)Q3%;2*$'LYB4Q`5'7&(M1K<WEA1C,3I3VDG^U.3XS@28\D90L!$`0<`M+
MS<:@<'7'7I1>-XR[337@O8"QH],8MK^Q'E.9TWF]X3!O6)VN3I$"J0&*U[1"
M'-RP_/:T0,DE)DV2\C^0H3E&A"VDHQ+=)O#.M>;1`EQ03K8"NY9.9$L;RTR)
M0B8=D[PCM-B=!GA7(S\DGTBH1!">`9BC&30>DO(<8`$-L\4_$!O5*..K42<Z
M^<X=\:^559%-1NSV2F:[HB#OD5KQTL8)\TET91O>;-1*'A8V2][7%JU!Y)2@
M:H)F#"RQ8R6$-FZJ\=D#L?E]K>47%S53SD0VGXW"'N2R>DI1KJJ;T4`029F4
M,B9K=+98IDZP)B>FF5RY$N$W@/6N0%Z`:<U.6).IP0'<XK$B?;GR/N9?<Y2G
M`[1_6=LC6HL`7F&)E*5K>4BMMKIV5,XB`Y+"<<GH!WSDS&<#"2[&!%G.3!]!
ME_EI21\G^N6C>B4-4B!,-W-W*[AY:1,6!0N5QZ+@"U'8()$9C/H33>Q(^>(6
M09#CVL8$(..^!`T/^+HC^)OPM]/!]A_CO\7?2NP?1]H_;7VG]/[=O1Z/HW[?
M;MV[=!1'R0>/%3O)?NS`-R;>V.M*.CKZ/UG$FVI&&+1%=$U$8KR4.DL4M)CJ
MX_\`)@#*G-\6Y5&9`8,O!_8/<(`AP##_`.O;^'Z_^/\`W_KT"W^MWCFUEK/R
M=.G)[%-JK2D%BOENW?:;M74F@T-71=43>X)LFDT8"]?)^NIRFQ%-S@(EH,X4
M`$G+$+`@Y&`0;UY;^`S4/EQ=8?8=E/DWIR^(,Q`B+5<5:_2%2U\A1*]>YHXA
M.(R_I5+7(VIH<G96H0'%&(5Z4Q28'Y`R1>ST%8.KOANZ4U9.XY-]G]@[DV]1
MQ,:03373DU-]3URO);U.%")LDR%I?I?+W-B(P'`<HDCTW$&]Q8,P,L0B\A&G
MS4K@8ZZU8T9T_A9+/&V2465*[*S#(\@2-+8QQ&D(2A@<-;432@)(0-3"4;9Y
MY2-.26`H&$'I`$(2^W0>C%_$"UUV%UMT]L=%?5E:PVX]ZPT>5L8P12+,TVB<
MYF*R(-3U,G1,W.3O&5\;D;BL6X3*A_)6MYAB(L_*/)PCC#@8AXL>%[3GB8B+
MXDH1HD$OM>;H$[=8M\6.J0N5A2AL(,3*P1EO`V(FYDB4+3N:;"DMN0IPB--P
M`:L]48448`(PP_Q]J?8N6UQY;I1L-9T[LM39TSLYOJAVC$230EL7/\&>*_BS
M2%W+R>]J$-?L;@FR@'V`:(YO)$+(?UQT'/(CX^]0<D6\U3[JV_L/9K+BI6FJ
MXVU4TRQB++X:XQFMILZ3I6S*G-U,,7E8F+H^+`+#`E9R`L[&,8%Z,=!=!L9K
MU4NU]'69KI>T333:IK<BJZ(S2-J3CDHE3>KR4>F6MS@E$6M:'YC<DQ"YN7)Q
M@4H5Z8E04()A818!9*O_`!M]O=3CSXAQ]<VFS^MU#.DB6NJJI)%`4U@I6%(N
M<`JSC8^)%8<2B6'TXHPS"A64QH!JC`A$;D7?.,!(11XSVN5AUY=2G:C9;8K<
M;:ZY:V4UJ1MCL0ZH)V^TZUK#DAJE31]</)B^-PE0(*<99)IZEQ6(BSS`I%*<
M)AN!A<^SZ5T65I+&M!)?&29_K\RZ^1?6]U8'T`$)TE@T9A;;"RU:PUCPWY:W
MY4G;0+`JT.4YJ1?V/3B+,``007RA/C&V=293I6.M/-%R!4'JBXN[XO*U^ACR
MJ0GMJ&1B/&\(6^81^>Q>-)E2X9N,FJ@18(C1>H9@!FCR9T%YW'WQOZP\9]*'
MTQK+&%Z3ZZZ&R2Q+,FBPF26G;$O-":'$FL.5%I&S+L>D+.$6D1IRDC>B+$/V
M""QG'F&!JKBXXN(+QAPZ_F6.6O,[OF.R%Y/5ZV/8\]9F!D?U[\\MR-+EI"FC
MP,)AMR5PPN6A$/.1_(<CNW8/;'0<;8\6T!V\WIT@W9G]IS!M.T8<'E_@%0MK
M*P*HG))6[.:=YQ(GIX<`G.B)2F=&9H-P!.#O_P`87V$$0LC"%I7\NWZ_Z_S_
M`/O0'0'0'0'0'0+`\YW_`$"_Y$43_P!OOW[^6/Q?G\/_`$S_`"<^S?L/[X>/
MJ/R/PU_^*^=]R^Y\_P"=_>?%^/[O['L]`SBV_`^G(/I7QOI?PDOTWX?H^)\#
IV"_A_%]O]OXWQ_3Z/3^GI[=OTZ#N]`=`=`=`=`=`=`=`=`=`=`=!_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
